Back

Panelists explore challenges in diagnosing and managing Sjogren’s Disease, evaluate emerging therapies, and share key considerations for integrating novel treatments into clinical practice.

Advancing Sjogren’s Disease Care: Emerging Therapies and Clinical Insights

Episodes

Specialty:

All

Year:

All

EP. 1: From Syndrome to Disease: Understanding the New Sjogren’s Nomenclature

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 2: Pathogenesis of Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 3: Recognizing Initial Symptoms of Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 4: Diagnostic Approaches in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 5: Diagnostic Challenges in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 6: Understanding Disease Progression and Lymphoma Risk in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 7: Impact of Sjogren’s Disease on Patient Quality of Life

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 8: Current Treatment Options in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 9: Therapeutic Sequencing in Sjogren’s Disease: Approaches and Unmet Needs

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 10: Barriers to Developing Disease-Modifying Therapies in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 11: Efficacy and Safey of Ianalumab in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 12: Additional Emerging Therapies in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 13: Strategies for Translating Clinical Trial Data into Practice for Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 14: Integrating Emerging Therapies into Clinical Practice for Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

EP. 15: Shared Decision-Making and Future Directions in Sjogren’s Disease

ByGhaith Noaiseh, MD,Teja Kapoor, MD,Thomas Grader-Beck, MD,Nehad Soloman, MD, FACR

November 24th 2025

Advancing Sjogren’s Disease Care: Emerging Therapies and Clinical Insights

Episodes

EP. 1: From Syndrome to Disease: Understanding the New Sjogren’s Nomenclature

EP. 2: Pathogenesis of Sjogren’s Disease

EP. 3: Recognizing Initial Symptoms of Sjogren’s Disease

EP. 4: Diagnostic Approaches in Sjogren’s Disease

EP. 5: Diagnostic Challenges in Sjogren’s Disease

EP. 6: Understanding Disease Progression and Lymphoma Risk in Sjogren’s Disease

EP. 7: Impact of Sjogren’s Disease on Patient Quality of Life

EP. 8: Current Treatment Options in Sjogren’s Disease

EP. 9: Therapeutic Sequencing in Sjogren’s Disease: Approaches and Unmet Needs

EP. 10: Barriers to Developing Disease-Modifying Therapies in Sjogren’s Disease

EP. 11: Efficacy and Safey of Ianalumab in Sjogren’s Disease

EP. 12: Additional Emerging Therapies in Sjogren’s Disease

EP. 13: Strategies for Translating Clinical Trial Data into Practice for Sjogren’s Disease

EP. 14: Integrating Emerging Therapies into Clinical Practice for Sjogren’s Disease

EP. 15: Shared Decision-Making and Future Directions in Sjogren’s Disease

Trending on HCPLive

Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy

Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD

Bimekizumab Data Support Case for Earlier Intervention in HS

One Year of Brensocatib: How Bronchiectasis Care Has Changed

Choosing the Right Plaque Psoriasis Patient for Icotrokinra